NMRK1 and neoplasm: The selective vulnerability of IDH1R132H cells to knockdown of NAMPT and NMRK1 indicated that these cells used both pathways to synthesize NAD+, making both enzymes possible targets for the selective treatment of IDH1 mutated tumor cells.